Intrinsic and acquired resistance mechanisms of alectinib in ALK rearranged cells

被引：0
|
作者：
Hibino, Yukiko [1 ]
Takaaki, Sasaki [1 ]
Minami, Yoshinori [1 ]
Janne, Pasi A. [2 ]
Ohsaki, Yoshinobu [1 ]
机构：
[1] Asahikawa Med Univ, Asahikawa, Hokkaido, Japan
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Activating alternative receptor tyrosine kinases induced alectinib-resistance in ALK rearranged non-small cell lung cancer cells
    Isozaki, Hideko
    Ichihara, Eiki
    Yasugi, Masayuki
    Takigawa, Nagio
    Ohashi, Kadoaki
    Kubo, Toshio
    Ninomiya, Takashi
    Ochi, Nobuaki
    Minami, Daisuke
    Kudo, Kenichiro
    Kato, Yuka
    Kayatani, Hiroe
    Tamura, Tomoki
    Ninonniya, Kiichiro
    Higo, Toshio
    Makimoto, Tsuyoshi
    Sato, Akiko
    Hotta, Katsuyuki
    Matsumoto, Kunio
    Sendo, Toshiaki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2016, 76
  • [32] Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
    Tani, Tetsuo
    Yasuda, Hiroyuki
    Hamamoto, Junko
    Kuroda, Aoi
    Arai, Daisuke
    Ishioka, Kota
    Ohgino, Keiko
    Miyawaki, Masayoshi
    Kawada, Ichiro
    Naoki, Katsuhiko
    Hayashi, Yuichiro
    Betsuyaku, Tomoko
    Soejima, Kenzo
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (01) : 162 - 171
  • [33] Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report
    Cesaro, Cristiano
    Caterino, Umberto
    Perrotta, Fabio
    Masi, Umberto
    Cotroneo, Alessandra
    Cianci, Roberta
    Zamparelli, Enzo
    Cesaro, Flavio
    Amore, Dario
    Rocco, Danilo
    MONALDI ARCHIVES FOR CHEST DISEASE, 2023, 93 (03)
  • [34] Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
    Rao, Chuangzhou
    Nie, Liangqin
    Wu, Xiaokang
    Miao, Xiaobo
    Chen, Ting
    Chen, Liuxi
    Zhang, Dongqing
    Lin, Quan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination
    Urbanska, E. M.
    Melchior, L. C.
    Sorensen, J. B.
    Santoni-Rugiu, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S645 - S646
  • [36] SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
    Xia, G.
    Yu, S.
    Ni, J.
    Song, M.
    Zhang, J.
    Huang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S526 - S527
  • [37] Mechanisms of acquired resistance to ALK/ROS1 inhibitors
    Shaw, Alice T.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [38] Src mediates acquired resistance to ALK inhibitor in ALK-rearranged non-small cell lung cancers
    Yoshida, Ryohei
    Okumura, Shunsuke
    Sasaki, Takaaki
    Osaki, Yoshinobu
    CANCER RESEARCH, 2016, 76
  • [39] Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy
    Tsui, David Chun Cheong
    Aisner, Dara
    Nijmeh, Hala
    Bao, Liming
    Menter, Alexander
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2022, 23 (02) : E99 - E103
  • [40] Rapid acquired resistance to alectinib in ALK-positive lung cancers with high tumor mutation burden
    Ohashi, Kadoaki
    Makimoto, Go
    Tomida, Shuta
    Nishii, Kazuya
    Toyooka, Shinichi
    Kiura, Katsuyuki
    CANCER RESEARCH, 2019, 79 (13)
12345